Home LiteratureArticle Details
PMID: 30554553 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Antibody response to feline panleukopenia virus vaccination in cats with asymptomatic retrovirus infections: a pilot study.

Journal of feline medicine and surgery ·Vol. 21 ·No. 12 ·2019-00-00 ·页码 1094-1101

Bergmann M, Schwertler S, Speck S, Truyen U, Hartmann K

Abstract

Currently, there are only a few studies on how immunocompromised cats, such as cats infected with feline leukaemia virus (FeLV) and feline immunodeficiency virus (FIV), respond to vaccination. Therefore, this study measured feline panleukopenia virus (FPV) antibodies in retrovirus-infected cats within a period of 28 days after FPV vaccination, and compared the immune response to that of non-infected cats. Eight asymptomatic retrovirus-infected cats (four FeLV, four FIV), and non-infected age-matched control cats (n = 67) were vaccinated with a commercial FPV modified live virus (MLV). Pre- and post-vaccination antibody titres were measured by haemagglutination inhibition (HI) on days 0, 7 and 28. An HI titre ⩾1:40 was defined as protective. An adequate response to vaccination was defined as a four-fold titre increase or higher. Comparison of the immune response of retrovirus-infected and non-infected cats was performed. Pre-vaccination FPV antibody titres ⩾1:40 were present in 100% (n = 8/8; 95% confidence interval [CI] 62.8-100) of retrovirus-infected and in 77.6% (n = 52/67; 95% CI 66.2-86.0) of non-infected cats. An adequate response to vaccination (titre increase ⩾four-fold) was seen in 1/8 retrovirus-infected cats (12.5%; 95% CI 0.1-49.2) compared with 22/67 non-infected cats (32.8%; 95% CI 22.8-44.8). In cats with high pre-vaccination titres (⩾1:160), a four-fold titre increase or higher was observed in 1/8 retrovirus infected cats (12.5%; 95% CI 0.1-49.2) compared with 4/42 non-infected cats (9.5%; 95% CI 3.2-22.6). None of the eight retrovirus-infected cats developed illness or vaccination side effects after vaccination with MLV against FPV within the 28 days. There were no significant differences between groups: for pre-vaccination titres; for at least four-fold titre increases following vaccination in either all cats or the cats with high pre-vaccination titres; and concerning adverse effects. All retrovirus-infected asymptomatic cats had pre-vaccination FPV antibodies indicating protection against panleukopenia. Response of retrovirus-infected cats to vaccination was similar to the response of non-infected cats.

Keywords
FIV FPV FeLV active immunisation immunosuppression protection
MeSH 主题词
Animals Antibodies, Viral/immunology Antibody Formation Asymptomatic Infections Cats Feline Panleukopenia/prevention & control Feline Panleukopenia Virus/immunology Female Hemagglutination Inhibition Tests/veterinary Male Pilot Projects Retroviridae Infections/etiology Vaccination/veterinary Viral Vaccines/immunology
化学物质
Antibodies, Viral Viral Vaccines
作者与单位
共 5 位作者,点击展开单位 / ORCID
Bergmann Michèle ORCID
Clinic of Small Animal Medicine, Centre for Clinical Veterinary Medicine, LMU, Munich, Germany.
Schwertler Stephanie
Clinic of Small Animal Medicine, Centre for Clinical Veterinary Medicine, LMU, Munich, Germany.
Speck Stephanie
Institute of Animal Hygiene and Veterinary Public Health, University of Leipzig, Leipzig, Germany.
Truyen Uwe
Institute of Animal Hygiene and Veterinary Public Health, University of Leipzig, Leipzig, Germany.
Hartmann Katrin
Clinic of Small Animal Medicine, Centre for Clinical Veterinary Medicine, LMU, Munich, Germany.
Article Info
Journal
Journal of feline medicine and surgery
Abbr.
J Feline Med Surg
ISSN
1532-2750
Published
2019-00-00
电子出版
2018-00-17
页码
1094-1101
Language
English
Country/Region
England
NLM ID
100897329
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]